ATE249838T1 - Konserviertes motiv der hepatitis c virus e2/ns1 region - Google Patents

Konserviertes motiv der hepatitis c virus e2/ns1 region

Info

Publication number
ATE249838T1
ATE249838T1 AT94915985T AT94915985T ATE249838T1 AT E249838 T1 ATE249838 T1 AT E249838T1 AT 94915985 T AT94915985 T AT 94915985T AT 94915985 T AT94915985 T AT 94915985T AT E249838 T1 ATE249838 T1 AT E249838T1
Authority
AT
Austria
Prior art keywords
motif
region
virus
hcv
hepatitis
Prior art date
Application number
AT94915985T
Other languages
German (de)
English (en)
Inventor
Amy J Weiner
Michael Houghton
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22037528&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE249838(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE249838T1 publication Critical patent/ATE249838T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • C07K16/118—Hepatitis C virus; GB virus C [GBV-C]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/82—Hepatitis associated antigens and antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT94915985T 1993-05-12 1994-05-03 Konserviertes motiv der hepatitis c virus e2/ns1 region ATE249838T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6169993A 1993-05-12 1993-05-12
PCT/US1994/004853 WO1994026306A1 (en) 1993-05-12 1994-05-03 Conserved motif of hepatitis c virus e2/ns1 region

Publications (1)

Publication Number Publication Date
ATE249838T1 true ATE249838T1 (de) 2003-10-15

Family

ID=22037528

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94915985T ATE249838T1 (de) 1993-05-12 1994-05-03 Konserviertes motiv der hepatitis c virus e2/ns1 region

Country Status (7)

Country Link
US (6) US6692907B1 (https=)
EP (2) EP1421951A3 (https=)
JP (3) JPH08510240A (https=)
AT (1) ATE249838T1 (https=)
CA (1) CA2162557C (https=)
DE (1) DE69433160T2 (https=)
WO (1) WO1994026306A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08510240A (ja) * 1993-05-12 1996-10-29 カイロン コーポレイション Ｃ型肝炎ウイルスｅ２／ｎｓ１領域の保存モチーフ
DE19504302A1 (de) * 1995-02-09 1996-08-14 Boehringer Mannheim Gmbh Methode zur serologischen Typisierung mittels typspezifischer Antigene
US6110465A (en) * 1995-06-07 2000-08-29 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of hypervariable region 1 of the envelope 2 gene of isolates of hepatitis C virus and the use of reagents derived from these hypervariable sequences in diagnostic methods and vaccines
KR970065713A (ko) * 1996-03-19 1997-10-13 성재갑 C형 간염 바이러스(일본형)의 분비형 외피 단백질 1 및 2
GB9810756D0 (en) 1998-05-19 1998-07-15 Angeletti P Ist Richerche Bio Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof
AU7602800A (en) * 1999-09-23 2001-04-24 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
EP1239876B1 (en) * 1999-11-19 2008-07-30 Csl Limited Hcv vaccine compositions
EP1256348B1 (en) * 2000-02-14 2012-05-02 Mitsubishi Tanabe Pharma Corporation Remedies for hepatitis c
WO2009021063A2 (en) * 2007-08-06 2009-02-12 The Regents Of The University Of California Composition and method of use for hcv immunization
US8314371B2 (en) 2008-11-06 2012-11-20 Applied Materials, Inc. Rapid thermal processing chamber with micro-positioning system
US20100322943A1 (en) 2009-06-17 2010-12-23 Thomas Cantor Therapeutic and diagnostic affinity purified specific polyclonal antibodies
FR2984328B1 (fr) 2011-12-20 2016-12-30 Bio-Rad Innovations Procede de detection d'une infection par le virus de l'hepatite c
GB201415714D0 (en) * 2014-09-05 2014-10-22 Medical Res Council Antibodies and antigen binding fragments thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6039948A (en) * 1973-05-07 2000-03-21 The Ohio State University Method for treatment of antigenically modified polypeptides
US4491632A (en) 1979-10-22 1985-01-01 The Massachusetts General Hospital Process for producing antibodies to hepatitis virus and cell lines therefor
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
CA1188985A (en) 1980-07-01 1985-06-18 National Research Development Corporation Production of viral antigens
EP0043718B1 (en) 1980-07-07 1984-11-28 National Research Development Corporation Improvements in or relating to cell lines
US4341761A (en) 1980-07-25 1982-07-27 E. I. Du Pont De Nemours And Company Antibodies to immunogenic peptides and their use to purify human fibroblast interferon
US4466917A (en) 1981-02-12 1984-08-21 New York University Malaria vaccine
US4493890A (en) 1981-03-23 1985-01-15 Miles Laboratories, Inc. Activated apoglucose oxidase and its use in specific binding assays
US4399121A (en) 1981-11-04 1983-08-16 Miles Laboratories, Inc. Iodothyronine immunogens and antibodies
US4427783A (en) 1981-12-14 1984-01-24 Hoffmann-La Roche Inc. Immunoassay of thymosin α1
DE3382547D1 (de) 1983-01-12 1992-05-27 Chiron Corp Sekretorische expression in eukaryoten.
CA1341302C (en) 1983-02-22 2001-10-09 Rae Lyn Burke Yeast expression systems with vectors having gapdh or pyk promoters and synthesis of foreign protein
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3587759T2 (de) 1984-05-11 1994-07-07 Chiron Corp., Emeryville, Calif. Erhöhte Hefetranskription unter Verwendung einer Hybridkonstruktion der Promotorregion.
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4629783A (en) 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
CA1319101C (en) 1986-09-03 1993-06-15 Marta Iris Sabara Rotavirus nucleocapsid protein with or without binding peptides as immunologic carriers for macromolecules
NZ227011A (en) 1987-11-18 1992-03-26 Chiron Corp Non-a, non-b-hepatitis (hepatitis c) antigens, proteins, nucleotide sequences, vaccines and kits
US5252459A (en) 1988-09-23 1993-10-12 Abbott Laboratories Indicator reagents, diagnostic assays and test kits employing organic polymer latex particles
KR0185373B1 (ko) * 1989-03-17 1999-05-01 로버트 피. 블랙버언 Hcv 폴리단백질에서 유래되는 hcv 아미노산 서열 부분을 포함하는 폴리펩티드 및 그 사용
DK0398748T3 (da) 1989-05-18 2002-03-18 Chiron Corp NANBV-diagnostika: polynukleotider anvendelige til screening for hepatitis C virus
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5308750A (en) * 1989-12-22 1994-05-03 Abbott Laboratories Monoclonal antibodies to putative HCV E2/NS1 proteins and methods for using same
US5747239A (en) * 1990-02-16 1998-05-05 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines
CA2047792C (en) 1990-07-26 2002-07-02 Chang Y. Wang Synthetic peptides specific for the detection of antibodies to hcv, diagnosis of hcv infection and prevention thereof as vaccines
EP0842947B2 (en) * 1990-11-08 2009-03-18 Novartis Vaccines and Diagnostics, Inc. Hepatitis C virus asialoglycoproteins
US6274148B1 (en) * 1990-11-08 2001-08-14 Chiron Corporation Hepatitis C virus asialoglycoproteins
US5574132A (en) * 1991-04-05 1996-11-12 Biochem Immunosystems Inc. Peptides and mixtures thereof for detecting antibodies to hepatitis C virus (HCV)
WO1993000365A2 (en) 1991-06-24 1993-01-07 Chiron Corporation Hepatitis c virus (hcv) polypeptides
WO1993006126A1 (en) 1991-09-13 1993-04-01 Chiron Corporation Immunoreactive hepatitis c virus polypeptide compositions
JP3177983B2 (ja) 1992-02-05 2001-06-18 ダイキン工業株式会社 ポリテトラフルオロエチレン成形用粉末
US6165730A (en) 1992-03-06 2000-12-26 N.V. Innogenetics S.A. Hepatitis C virus peptides obtained from the NS4 coding region and their use in diagnostic assays
JPH08510240A (ja) * 1993-05-12 1996-10-29 カイロン コーポレイション Ｃ型肝炎ウイルスｅ２／ｎｓ１領域の保存モチーフ
EP0992580B1 (en) 1993-11-04 2005-03-09 Innogenetics N.V. Immunodominant human T-cell epitopes of Hepatitis C virus
US5709995A (en) 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
DK1354204T4 (da) * 2000-06-15 2010-06-14 Novartis Vaccines & Diagnostic HCV-antigen/antistof-kombinationssay

Also Published As

Publication number Publication date
EP0697888A1 (en) 1996-02-28
WO1994026306A1 (en) 1994-11-24
JP2005097319A (ja) 2005-04-14
US7135185B1 (en) 2006-11-14
CA2162557A1 (en) 1994-11-24
US7371386B2 (en) 2008-05-13
CA2162557C (en) 2004-09-28
EP1421951A3 (en) 2005-10-05
US20070014813A1 (en) 2007-01-18
JPH08510240A (ja) 1996-10-29
US7098303B1 (en) 2006-08-29
DE69433160T2 (de) 2004-07-08
US20030017156A1 (en) 2003-01-23
US7252827B1 (en) 2007-08-07
JP2005325126A (ja) 2005-11-24
EP0697888B1 (en) 2003-09-17
EP1421951A2 (en) 2004-05-26
US6692907B1 (en) 2004-02-17
DE69433160D1 (de) 2003-10-30

Similar Documents

Publication Publication Date Title
DE69433160D1 (de) Konserviertes Motiv der Hepatitis C Virus E2/NS1 Region
ATE236981T1 (de) Von menschlichen t-zellen immunodominante epiropen des virus der c-hepatitis
ATE507312T1 (de) Nachweis und typisierung das hepatitis c virus (hcv) mittels 5'utr und ns5 nukleinsäuresequenzen
SG50563A1 (en) New sequences of hepatitis c virus genotypes and their use as therapeutic and diagnostic agents
AU3844095A (en) New sequences of hepatitis c virus genotypes and their use as prophylactic, therapeutic and diagnostic agents
CA2032381A1 (en) Viral agent
NO904712L (no) Nanbv diagnostiske midler og vaksiner.
ATE224956T1 (de) Verfahren zur verstärkten expression von virusproteinen
CY2053B1 (en) Synthetic antigens for the detection of antibodies to hepatitis c virus
AU2197392A (en) Hepatitis C virus from C-100-3 and env/core regions
EP0342860A3 (en) Novel protein, sequences containing the gene therefore, vectors, methods of preparation and use
DK0551275T3 (da) Non-A non-B sekvenser
DE69901099D1 (de) Verwendung von interferon alpha 5 in der behandlung viraler hepatopathien
DK257887A (da) Fremgangsmaade til fremstilling af hbcag i gaer og plasmid til brug ved udoevelse af fremgangsmaaden
SG145521A1 (en) Synthetic antigens for the detection of antibodies to hepatitis c virus

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0697888

Country of ref document: EP

RZN Patent revoked